Corporate Advisory Board

Keith Flaherty, MD
Dr. Flaherty is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Cancer Center at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer and to define the mechanisms of action and resistance of novel therapies. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute and has been the principal investigator of many clinical trials, including first-in-human trials of novel targeted therapies. He is a member of numerous scientific cancer societies and national committees, and has authored many research articles, abstracts and reviews in the peer-reviewed literature; including 3 first-author New England Journal of Medicine papers. He serves as a senior editor for Clinical Cancer Research and a member of the editorial boards for Cancer Discovery, Journal of Clinical Oncology, Cancer, and Pigment Cell and Melanoma Biology.

Dr. Flaherty obtained his undergraduate degree from Yale University in 1993 and an MD from Johns Hopkins University in 1997. He completed his internship in medicine, followed by a residency in medicine, at Brigham and Women’s Hospital (Harvard Medical School) in Boston. He went on to complete a fellowship in Medical Oncology at the Hospital of the University of Pennsylvania.
Alison Lawton
Ms. Lawton has more than 30 years of global pharmaceutical and biotechnology experience. She is Chief Operating Officer of Aura Biosciences and serves on the board of directors of Verastem, Inc., and ProQR Therapeutics. Previously, Ms. Lawton was COO at OvaScience. Prior to that, she spent 23 years in various positions of increasing responsibility at Genzyme Corporation where she held several senior roles including Senior Vice President and General Manager of the Biosurgery Business and Senior Vice President of Global Market Access. In addition, she led the regulatory team for the approval of plerixafor, a CXCR4 inhibitor, in 2008. Ms. Lawton currently sits on the scientific advisory board for the Massachusetts Life Science Center. Alison is also past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for the Cell and Gene Therapy Committee.

Ms. Lawton earned her BS in Pharmacology, with honors, from King’s College London.
Howard Pien
Mr. Pien has worked in the pharmaceutical and biotechnology industries for over 30 years and is currently the Chairman of the Board of Juno Therapeutics and a Board member of Indivior PLC, Immunogen, Inc., Sage Therapeutics, Inc., and Vanda Pharmaceuticals. Previously, Mr. Pien was the Chairman and CEO of Medarex, Inc., a public biotechnology company developing immuno-oncology agents, until it was acquired by Bristol-Myers Squibb. He also served as the Chairman and CEO of Chiron, a public biotechnology company, which was acquired by Novartis. His previous Board directorships include Bellerophon, Talon, Arresto, Ikaria and Viropharma (where he was lead independent director). Mr. Pien has also held board appointments at the industry associations BIO and PhRMA, as well as Oakland Children’s Hospital and Fox Chase Hospital.

Mr. Pien graduated from MIT with a BS in engineering, and from Carnegie-Mellon University with an MBA.
Mike Vasconcelles, MD
Dr. Vasconcelles is an industry veteran with over 25 years of experience and currently the Chief Medical Officer at Unum Therapeutics. He previously served as Senior Vice President and Global Head for Oncology at Takeda Pharmaceuticals where he led the development of the oncology portfolio from candidate selection through life cycle management. Before that, Dr. Vasconcelles was Vice President, Personalized Medicine and Companion Diagnostics at Sanofi and Group Vice President and Global Therapeutic Area Head of Transplant and Oncology at Genzyme Corporation. He currently holds positions as a Clinical Instructor in Medicine at Harvard Medical School and as a staff physician at two prestigious institutions: Dana-Farber Cancer Institute and Brigham & Women’s Hospital in Boston, Massachusetts.

He received his B.A. from Northwestern University, and his M.D. from Northwestern University’s Feinberg School of Medicine. He completed his postgraduate training in internal medicine at Beth Israel Hospital and went on to complete a fellowship in hematology and oncology at Brigham and Women's Hospital.